Comments on “Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7–Blocking Therapy in Inflammatory Bowel Disease”
We read with great interest the study by Horn et al1 on circulating effector CD4+ T cells as predictors of response to integrin α4β7–blocking therapy in inflammatory bowel disease (IBD). Their integration of mass cytometry, single-cell sequencing, and machine learning provides a comprehensive approach to identifying immune signatures associated with vedolizumab response. However, several aspects warrant further discussion regarding biomarker validation, multi-omics integration, and therapeutic implications.
